



HAL
open science

**Author reply to comment by Brandenburg et al. on:
Large differences between test strategies for the
detection of anti-Borrelia antibodies are revealed by
comparing eight ELISAs and five immunoblots**

C. W. Ang

► **To cite this version:**

C. W. Ang. Author reply to comment by Brandenburg et al. on: Large differences between test strategies for the detection of anti-Borrelia antibodies are revealed by comparing eight ELISAs and five immunoblots. *European Journal of Clinical Microbiology and Infectious Diseases*, 2011, 30 (8), pp.1035-1037. 10.1007/s10096-011-1301-3. hal-00702655

HAL Id: hal-00702655

<https://hal.science/hal-00702655>

Submitted on 31 May 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Dear Editor,

We thank our colleagues for their valuable contribution and comments. First, we completely agree that for a thorough judgment of any assay samples from clinically well defined patients are necessary. Brandenburg et al correctly state that with the results from the current study, it can not be concluded which test is the best and it is difficult to discriminate between increased sensitivity and decreased specificity (both leading to an increased number of positive tests). However, this study did not aim to describe a sensitivity for any assay for certain patient groups, nor to define the “best test” but to demonstrate that the results of antibody testing for Borrelia are highly influenced by the choice of assay. The harsh truth is that even in a country as The Netherlands, with more than 10 assays and 6 immunoblots commercially available, every day many potentially discrepant results are generated.

The patients with skin manifestations were predominantly erythema migrans patients, the neurological patients included only 7 patients with symptoms of short duration. We did not observe more discrepant results in the patients with documented symptoms of short duration. The 6 ELISA positive, blot negative patients were predominantly neurological patients. In half of the patients there was a longer disease duration, making the possibility of an early manifestation of neuroborreliosis less likely. In only 1 of these patients, a concordant result in more than one immunoblot was present (IgG antibody reactivity in a patient with chronic pain throughout the body). From our data it is impossible to conclude that immunoblots are more sensitive or less specific and more extensive studies using appropriate samples from patients with possible cross reacting or aspecifically reacting samples are needed to solve this issue.

For interpretation of Borrelia serology, clinical information is indispensable. Part of the discrepancies between the tests will be resolved when taking into account the clinical picture (e.g. isolated low IgM seropositivity in a patient with chronic complaints is suspicious for false-positivity, even with a positive immunoblot). Recognition of a Borrelia infection in “typical” case of Lyme disease (erythema migrans, monoarthritis of the knee with a history of tick bite etc.) will not pose a problem in many cases and multiple studies demonstrate high sensitivity for serological tests in these selected patient groups. However, for clinical syndromes with a low a priori chance of Borrelia infection (facial nerve paralysis, sudden deafness, chronic joint pain etc.) there is no clinical “gold standard” and we have to rely on serological tests.

Our samples include 6 patients with “definite Lyme disease” (5 erythema migrans, 1 neuroborreliosis), 37 without Lyme disease (patients with an alternative diagnosis and the control patients) and 46 samples from patients with complaints that were compatible with Lyme disease but not typical. For this group of patients Borrelia antibody testing was performed in order to make a diagnosis (“possible Lyme disease”). This last group forms the most interesting group and the results in this group probably illustrate our message most clearly. In 31 samples that were tested in all 8 ELISA’s and all 5 blots there were 24 samples from patients with “possible Lyme” (extra table). From these 24 patients, 12 had a positive ELISAxBlot combination and 5 of these 12 were positive in all 40 combinations. Therefore there were discrepancies in $7/24 = 29\%$ of these patients. However, the patients in this study were partly selected based on reactivity in one screening test (VIDAS) and the observed percentage discrepancies may be overestimated.

Extra Table - Elisa x Blot combinations per diagnosis group in 31 samples

Number of positive ELISA x Blot combinations	Definite Lyme	Possible Lyme	Definite NO Lyme
---	----------------------	----------------------	-------------------------

0	0	12	1
1-8	0	4	1
9-23	0	1	1

24-39	2	2	0
40	2	5	0

Total number of patients	4	24	3
--------------------------	---	----	---

To circumvent the problem of biased agreement due to the inclusion of “indeterminate” results, we scored all “indeterminate”, “grey zone” and “borderline” results as negative. Separate agreement analysis of IgG and IgM did not alter our conclusions. Kappa values for IgG ranged from 0,48 to 0,94, while for IgM there was generally less agreement with kappa’s ranging from 0,32 to 0,68.

IgM

ELISA manufacturer	Antigen used for ELISA	Moran	Virion/Serion	Enzygnost	Euroimmun	Virotech	Mediphos
Moran	Whole cell	-	-	-	-	-	-
Virion/Serion	Whole cell + VIsE	0,39	-	-	-	-	-
Enzygnost	Whole cell + VIsE	0,32	0,72	-	-	-	-
Euroimmun	Whole cell + VIsE	0,59	0,52	0,43	-	-	-
Virotech	Whole cell + VIsE	0,39	0,68	0,53	0,36	-	-
Mediphos	Recombinant	0,59	0,44	0,34	0,68	0,44	-

IgG

ELISA manufacturer	Antigen used for ELISA	Moran	VIDAS	Virion/Serion	Enzygnost	Euroimmun	Virotech	Immunetics	Mediphos
Moran	Whole cell	-	-	-	-	-	-	-	-
VIDAS	Whole cell	0,52	-	-	-	-	-	-	-
Virion/Serion	Whole cell + VIsE	0,74	0,48	-	-	-	-	-	-
Enzygnost	Whole cell + VIsE	0,85	0,59	0,74	-	-	-	-	-
Euroimmun	Whole cell + VIsE	0,73	0,46	0,64	0,76	-	-	-	-
Virotech	Whole cell + VIsE	0,51	0,56	0,49	0,48	0,6	-	-	-
Immunetics	Recombinant	0,79	0,6	0,71	0,94	0,71	0,49	-	-
Mediphos	Recombinant	0,82	0,57	0,79	0,91	0,73	0,5	0,85	-

In conclusion, we think that our study certainly has limitations but our data clearly demonstrate that the results for Borrelia antibody testing is highly influenced by the laboratory method. The discrepancies in test results are partly resolved by taking into account clinical data and disease duration. We applaud any initiative aimed at increasing the availability of clinical data for laboratories. There will always

remain a substantial group of patients in which the decision whether symptoms are attributable to a *Borrelia* infection crucially depends on the results of serological testing. Our study illustrates that also in this group the choice of assay partly determines the result and we hope that future harmonization and standardization will minimize the group of patients with discrepant results.

Sincerely,

Also on behalf of all co-authors,
C.W. Ang, MD, PhD
Department of Medical Microbiology and Infection Control
VU University Medical Center
P.O. Box 7057
1007 MB, Amsterdam
The Netherlands
phone: +31.20.444.0479
e-mail: w.ang@vumc.nl